Sun Pharma, Ranbaxy integration to be over by Feb-end: Dilip Shanghvi

G Naga Sridhar Hyderabad | Updated on January 24, 2018 Published on January 25, 2015

Sun Pharma chief Dilip Shanghvi   -  BUSINESS LINE

Sun Pharmaceuticals Ltd is likely to complete the integration of Ranbaxy by end of next month if all regulatory approvals come as expected, according to its founder - Managing Director, Dilip S Shanghvi.

Speaking to newspersons on the sidelines of a book release function held here on Friday, Shanghvi said the fourth quarter results could actually reflect the numbers for the combined entity.

"We have the issue coming up in High Court on February 2, 2015. Once we get the approval, by middle of February, we should be able to close the deal and have a combined entity,’’ he said.

In April last year, Sun Pharma announced its plans to buy out Ranbaxy in a $4-billion (including $800-million debt), all-stock deal, in the process creating India’s largest drug company.

Asked on the key challenges in the process of integration, Shanghvi identified differences in product portfolio as one.

"Product portfolio (of Ranbaxy) would be different from that of us. Also they have significance presence in countries where we have only small presence. As I see, these are important challenges for the future business,’’ he said.

Shanghvi, who is known for his penchant and expertise for management of human resources feels that Sun Pharma would have to help people in Ranbaxy who made that company successful while making them confident about their future.

On the plans for a new acquisition, he said: "Next acquisition may take a little longer. It depends on the issues of integration, among others.’’

On the issues concerning alleged delays in new drug approvals from the US Food and Drug Administration, Shanghvi said the FDA was now looking at various initiatives including those qualify for early approvals on various parameters.

Published on January 25, 2015

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.